609 related articles for article (PubMed ID: 18535873)
21. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.
Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F
J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752
[TBL] [Abstract][Full Text] [Related]
22. Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis.
Dimitroulopoulos D; Xynopoulos D; Tsamakidis K; Paraskevas E; Zisimopoulos A; Andriotis E; Fotopoulou E; Kontis M; Paraskevas I
World J Gastroenterol; 2004 Dec; 10(24):3628-33. PubMed ID: 15534919
[TBL] [Abstract][Full Text] [Related]
23. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
[TBL] [Abstract][Full Text] [Related]
24. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors.
Curran T; Tulin-Silver S; Patel K; Ward S; Schneiderman M; Harpaz N; Schwartz M; Itzkowitz S; Warner RR; Kim MK
Pancreas; 2011 Nov; 40(8):1253-7. PubMed ID: 21975435
[TBL] [Abstract][Full Text] [Related]
25. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study.
Gibril F; Reynolds JC; Lubensky IA; Roy PK; Peghini PL; Doppman JL; Jensen RT
J Nucl Med; 2000 Oct; 41(10):1646-56. PubMed ID: 11037994
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptor scintigraphy in metastatic breast cancer patients.
Mezi S; Primi F; Orsi E; Capoccetti F; Scopinaro F; Schillaci O
Oncol Rep; 2005 Jan; 13(1):31-5. PubMed ID: 15583798
[TBL] [Abstract][Full Text] [Related]
27. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.
Hubalewska-Dydejczyk A; Fröss-Baron K; Mikołajczak R; Maecke HR; Huszno B; Pach D; Sowa-Staszczak A; Janota B; Szybiński P; Kulig J
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1123-33. PubMed ID: 16721571
[TBL] [Abstract][Full Text] [Related]
28. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors.
Spanu A; Solinas ME; Farris A; Arru A; Chessa F; Madeddu G; Falchi A; Madeddu G
Radiol Med; 2004; 107(1-2):113-27. PubMed ID: 15031703
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
30. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.
Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD
Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study.
Dörr U; Würstlin S; Frank-Raue K; Raue F; Hehrmann R; Iser G; Scholz M; Guhl L; Buhr HJ; Bihl H
Horm Metab Res Suppl; 1993; 27():48-55. PubMed ID: 8330872
[TBL] [Abstract][Full Text] [Related]
32. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
Hoegerle S; Altehoefer C; Ghanem N; Koehler G; Waller CF; Scheruebl H; Moser E; Nitzsche E
Radiology; 2001 Aug; 220(2):373-80. PubMed ID: 11477239
[TBL] [Abstract][Full Text] [Related]
33. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
34. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors.
Gibril F; Jensen RT
Yale J Biol Med; 1997; 70(5-6):509-22. PubMed ID: 9825478
[TBL] [Abstract][Full Text] [Related]
36. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy.
Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M
J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670
[TBL] [Abstract][Full Text] [Related]
37. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
39. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
40. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]